EUCTR2005-000276-40-HU进行中（未招募）不适用
A RANDOMISED, OPEN TWO WAY CROSS-OVER STUDY TO ASSESS THE BRONCHODILATING PROPERTIES OF A NEW SALBUTAMOL-HFA 134a FORMULATION GIVEN AS CUMULATIVE DOSES AND A REFERENCE SALBUTAMOL-HFA 134a FORMULATION IN ADULT ASTHMATIC PATIENTS
GENERICS [UK] Ltd.0 个研究点目标入组 30 人开始时间: 2005年2月11日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •At study entry:
- •1.Male and female asthmatic patients, aged 18 - 45 years inclusive.
- •2. Documented asthma for at least 6 months before screening.
- •3.Subjects with a FEV1 between 50% and 85% of the predicted normal value for age, height and gender.
- •4.Subjects who demonstrate a reversibility of > 12% in FEV1 10 minutes after a dose of 200?g salbutamol from a standard salbutamol pMDI, after withholding short acting ?2-agonists for at least 6 hours and long acting ?2-agonists for at least 24 hours.
- •5.Subjects who are able to handle a pMDI correctly without the aid of air chambers.
- •6.Subjects who are willing to give written informed consent to participate in the study.
- •On study days:
- •1.A pre-dose baseline FEV1 within 10% of the value obtained at the Screening Visit.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patients currently receiving oral corticosteroid therapy or who have received oral corticosteroid therapy in the 3 months preceding the screening.
- •2.Patients currently receiving therapy for an upper respiratory tract infection or who have received such a therapy in the month prior to the start of the study.
- •3.Patients who have been hospitalised or received emergency treatment for an exacerbation of asthma in the 3 months prior to the start of the study.
- •4.Patients with a known or suspected hypersensitivity to salbutamol or it’s excipients.
- •5.Patients who have experienced bronchospasms following the administration of HFA 134a containing products.
- •6.Patients who are unable to perform lung function tests.
- •7.Patients with any of the following concurrent conditions:
- •Uncontrolled diabetes mellitus
- •Evidence of current neoplastic disease other than basal cell carcinoma
- •Evidence of tuberculosis
- •Evidence of significant cardiovascular disease
- •Respiratory disorders other than asthma or rhinitis
- •Significant hepatic or renal insufficiency.
- •Evidence or history of alcohol or drug abuse.
- •Evidence or history of low potassium levels.
- •8.Patients currently receiving other investigational medication or who have received investigational medication in the 3 months prior to the screening of the study.
- •9.Employees of Merck Generics [UK] Ltd. or the CRO responsible for the execution of the study.
- •10.Women who are pregnant, lactating or likely to become pregnant during the course of the study. Women of child bearing potential will be eligible to enter the study if using adequate contraception (i.e. contraceptive pill or barrier methods).
研究者
相似试验
进行中（未招募）
1 期
Comparison of two daily dose regimens of tiotropium 5 µg once daily and tiotropium 2.5 µg twice daily for 4 weeks on top of maintenance therapy with an inhaled corticosteroid controller medicatioMedDRA version: 15.0Level: LLTClassification code 10003555Term: Asthma bronchialSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2012-001873-10-SIBoehringer Ingelheim RCV GmbH & Co KG92
进行中（未招募）
不适用
Comparison of two daily dose regimens of tiotropium 5 µg once daily and tiotropium 2.5 µg twice daily for 4 weeks on top of maintenance therapy with an inhaled corticosteroid controller medicatioEUCTR2012-001873-10-DEBoehringer Ingelheim Pharma GmbH & Co. KG92
进行中（未招募）
不适用
Comparison of two daily dose regimens of tiotropium 5 µg once daily and tiotropium 2.5 µg twice daily for 4 weeks on top of maintenance therapy with an inhaled corticosteroid controller medicatioEUCTR2012-001873-10-HUBoehringer Ingelheim RCV GmbH & Co KG92
进行中（未招募）
不适用
Comparison of two daily dose regimens of tiotropium 5 µg once daily and tiotropium 2.5 µg twice daily for 4 weeks on top of maintenance therapy with an inhaled corticosteroid controller medicatioEUCTR2012-001873-10-ATBoehringer Ingelheim RCV GmbH & Co KG92
进行中（未招募）
1 期
A Randomized, Double-Blind, Two-Way Crossover Study to Determine the Bioequivalence of a Single Dose of Testim® 1% With Pentadecalactone 1% Relative to a Single Dose of Testim® 1% With Pentadecalactone 8% in Hypogonadal MalesSubjects will be hypogonadal men with an 0800 hr (±30 minutes) serum testosterone level = 350 ng/dLMedDRA version: 9.1Level: LLTClassification code 10021011Term: Hypogonadism maleEUCTR2007-001012-23-NLAuxilium UK Limited